HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

Benzinga Newsdesk www.benzinga.com Negative 85.5%

Neg 85.5% Neu 0% Pos 0%

HC Wainwright & Co. suspends Neutral rating on Atrium Therapeutics (NASDAQ:RNA).

Comments

No comments yet. Be the first!

HC Wainwright &amp; Co. Suspends Neutral Rating on Atrium Therapeutics